Clinical trials: Differentiated Thyroid Carcinoma
Head and Neck Cancer
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer
RATIONALE: Radioactive iodine uses radiation to kill tumor cells. Giving iodine I 131 with or without thyroid-stimulating hormone after surgery may kill any tumor cells that remain after surgery.
- Trial name
- HiLo (NCT00415233)
- Testing
- recombinant thyroid-stimulating hormone, Radiodine ablation without rhTSH
- Where
- 25 sites in United Kingdom
- Volunteers
- 438 people
- Sponsor
- University College, London
Thyroid Cancer
rhTSH-Thyroid Ablation With 1850 MBq of 131I
Most patients with differentiated thyroid carcinoma (DTC) are treated with therapeutic doses of radioiodine (131I) after initial surgery (total or near total thyroidectomy), aimed to destroy microscopic residual normal or tumoral…
- Trial name
- NCT00454077
- Testing
- radioiodine therapy after rhTSH
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- University of Siena
Head and Neck Cancer
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01118065
- Testing
- everolimus
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Leiden University Medical Center
Cancer, Thyroid Carcinoma
Thyroid Cancer and Sunitinib
Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this…
- Trial name
- THYSU (NCT00510640)
- Testing
- Sunitinib
- Where
- 15 sites in France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Differentiated Thyroid Cancer, Pediatric Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- NCT05783323
- Testing
- Larotrectinib monotherapy, 131I therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
This phase II trial studies how well encorafenib and binimetinib given with or without nivolumab works in treating patients with BRAF V600 mutation positive thyroid cancer that has spread to other places in the body (metastatic)…
- Conditions
- BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma
- Trial name
- NCT04061980
- Testing
- Binimetinib, Encorafenib, Nivolumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer.
- Conditions
- Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01208051
- Testing
- Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 33 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Cancer
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine…
- Trial name
- CABOTHYROID (NCT05660954)
- Testing
- Cabozantinib
- Where
- 9 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma, Thyroid Cancer, Thyroid Nodule
- Trial name
- THINC (NCT07907432)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Marmara University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Thyroid Gland
Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer
This project aims to study the effects of different types of thyroid surgery and RAIT on ovarian function and pregnancy outcomes of DTC women of childbearing age, analyze possible risk factors, and assess whether potential risk…
- Trial name
- NCT06845098
- Testing
- Total thyroidectomy, Total thyroidectomy + RAIT, Thyroid one-sided lobe + isthmus resection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Provincial People's Hospital
Thyroid Carcinoma, Thyroid Cancer
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors.
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell)
- Trial name
- NCT04462471
- Testing
- I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Differentiated Thyroid Gland Carcinoma
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Most thyroid cancers can be cured with surgery, sometimes with radioactive iodine therapy. However, some patients have cancer that has spread, and some have cancer that comes back after treatment.
- Trial name
- NCT06790589
- Testing
- Levothyroxine Oral Tablet [Synthroid]
- Volunteers
- 70 people
- Sponsor
- AHS Cancer Control Alberta
Differentiated Thyroid Cancer, Advanced Cancer
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC).
- Trial name
- NCT04321954
- Testing
- LENVATINIB
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Thyroid Neoplasms
Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer
A retrospective analysis was conducted on RAIR-DTC patients who underwent radioactive 125I seed implantation from January 2015 to February 2022 at Jiangxi Cancer Hospital. Prescription dose: 80~120 Gy.
- Trial name
- NCT06362772
- Testing
- Iodine-125 brachytherapy
- Volunteers
- 36 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Thyroid Cancer
Lateral Cervical Node Dissection in Differentiated Thyroid Cancer.
The objective of this study is to compare shoulder and neck morbidity and the effectiveness of cervical lateral nodal dissection in patients with differentiated thyroid cancer and lateral metastases between the anterior and…
- Trial name
- NCT06149637
- Testing
- Traditional neck dissection approach, Anterior neck dissection approach
- Where
- Colombia
- Volunteers
- 62 people
- Sponsor
- Centro de Excelencia en Enfermedades de Cabeza y Cuello
Thyroid Cancer
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
Progressive and metastatic thyroid cancer patients, who no longer respond to radioactive iodine (RAI), are currently treated with long term tyrosine kinase inhibitors to control tumor growth.
- Trial name
- NCT04554680
- Testing
- dabrafenib and trametinib
- Where
- Singapore
- Volunteers
- 5 people
- Sponsor
- National University Hospital, Singapore
Thyroid Gland Carcinoma
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.
- Trial name
- NCT06207188
- Testing
- Non-Interventional Study
- Where
- 3 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Differentiated Thyroid Cancer
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake Effects For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients
- Trial name
- NCT04137185
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd